Repeating genes

Huntington’s disease is a genetic time bomb: Programmed in the genes, it appears at a predictable age in adulthood, causing a progressive decline in mental and neurological function and finally death. There is, to date, no cure. Huntington’s, and a number of diseases like it, collectively known as trinucleotide repeat diseases, are caused by an unusual genetic mutation: A three-letter piece of gene code is repeated over and over in one gene.

Scientists at the Weizmann Institute have now proposed a mechanism that provides an explanation for the remarkable precision of the time bomb in these diseases. This explanation may, in the future, point researchers in the direction of a possible prevention or cure.

The number of repeats in Huntington’s patients ranges from 40 to over 70. Scientists have noted that, like clockwork, one can predict by how many times the sequence repeats in a patient’s gene both the age at which the disease will appear and how quickly the disease will progress. The basic assumption has been that the protein fragment containing the amino acid (glutamine) encoded in the repeating triplet slowly builds up in the cells until eventually reaching toxic levels.

This theory, unfortunately, fails to explain some of the clinical data. For instance, it doesn’t explain why patients with two copies of the Huntington’s gene don’t exhibit symptoms earlier than those with a single copy. Plus, glutamine is produced in only some trinucleotide diseases, whereas the correlation between sequence length and onset age follows the same general curve in all of them, implying a common mechanism not tied to glutamine.

Research student Shai Kaplan in Prof. Ehud Shapiro’s lab in the Biological Chemistry, and Computer Sciences and Applied Mathematics Departments, realized the answer might lie in somatic mutations – changes in the number of DNA repeats that build up in our cells throughout our lives. The longer the sequence, the greater the chance of additional mutation, and the scientists realized that the genes carrying the disease code might be accumulating more and more DNA repeats over time, until some critical threshold is crossed.

Based on the literature on some 20 known trinucleotide repeat diseases and their knowledge of the mechanisms governing somatic mutation, Shapiro, Kaplan (who is also in the Molecular Cell Biology Department) and Dr. Shalev Itzkovitz created a computer simulation that could take a given number of genetic repeats and show both the age of onset and the way in which the disease progresses. Their findings appeared in PLoS Computational Biology.

The new disease model appears to fit all of the facts and to provide a good explanation for the onset and progression of all of the known trinucleotide repeat diseases. Experimentation in research labs could test this model, say the scientists and, as it predicts that all these diseases operate by somatic expansion of a trinucleotide repeat, it also suggests that a cure for all might be found in a drug or treatment that slows down the expansion process.

Source: Weizmann Institute of Science

Related stories:

Landmark study opens door to new cancer, aging treatments
Researchers at The Wistar Institute have deciphered the structure of the active region of telomerase, an enzyme that plays a major role in the development of nearly all human cancers. The landmark achievement opens the door to the creation of new, broadly effective cancer drugs, as well as anti-aging therapies.
'Intrabody' can mop up mutant protein in Huntington's disease model
Scientists have created a tool for mopping up the clumps of mutant protein that drive neurodegeneration in Huntington's disease. Emory University researchers engineered a virus to make an intracellular antibody or "intrabody" against huntingtin, the protein whose mutant forms poison the brain cells of people with Huntington's.
RNA toxicity contributes to neurodegenerative disease, scientists say
Expanding on prior research performed at the University of Pennsylvania, Penn biologists have determined that faulty RNA, the blueprint that creates mutated, toxic proteins, contributes to a family of neurodegenerative disorders in humans.
Cancer drug may help patients with heart-lung disease
A drug developed to fight cancer is showing early promise as a treatment for pulmonary hypertension, researchers from the University of Chicago Medical Center report May 19 at the American Thoracic Society International Conference in Toronto, Canada.
Researchers develop first transgenic nonhuman primate model of Huntington's disease
In the first study of its kind, researchers at the Yerkes National Primate Research Center, Emory University, in collaboration with researchers from the Department of Human Genetics at Emory's School of Medicine, have developed the first transgenic nonhuman primate model of Huntington's disease (HD), one of the most devastating human neurodegenerative diseases.
Scientists Explore Factors Contributing to DNA Mutations
A team of Penn State University researchers is the first to conduct a genome-wide study to compare the relative importance of factors that contribute to DNA mutations, which are implicated in cancer and over 40 neurological disorders.
Huntington's disease problem start early
The damaging effects of the mutated protein involved in Huntington’s disease take place earlier in cell life than previously believed, said researchers from Baylor College of Medicine in Houston in a report that appears in the current edition of the journal Neuron.
Lab identifies elusive telomere RNA subunit in single cell model
The Stowers Institute’s Baumann Lab has identified the long-sought telomerase RNA gene in a single-cell research model. Their findings have been posted to the Web site of the journal Nature Structural & Molecular Biology and will appear in a future print edition.

News discussion:

General Science news